AbbVie Inc. which can be found using ticker (ABBV) have now 27 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $239.00 and $165.00 suggesting an average Analsyt target price of $204.90. Now with the previous closing price of $193.00 this now indicates there is a potential upside of 6.2%. It’s also worth noting that there is a 50 day moving average of $178.76 and the 200 day moving average is $180.08. The market cap for the company is 341.85B. Currently the stock stands at: $193.45 USD
The potential market cap would be $362,923,322,230 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 80.6, revenue per share of $31.40 and a 7.72% return on assets.
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
